Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy-Reference-Cited by-同舟云学术

Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy

Published:2017-11 Issue:5 Volume:266 Page:738-745
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Kalinowski Piotr,Paluszkiewicz Rafał,Ziarkiewicz-Wróblewska Bogna,Wróblewski Tadeusz,Remiszewski Piotr,Grodzicki Mariusz,Krawczyk Marek

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference32 articles.

1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;Marchesini;J Hepatol,2016

2. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world;Sayiner;Clin Liver Dis,2016

3. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the “Plague” of the 21st century? A literature review focusing on pathogenesis, prevention and treatment;Argyrou;J BUON,2017

4. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver;Pais;J Hepatol,2013

5. Bariatric surgery worldwide 2013;Angrisani;Obes Surg,2015

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laparoscopic Roux-en-Y Versus Mini-Gastric Bypass on Liver Function at 6 Months in Morbid Obesity Patients: A Cross-Sectional Study;Hepatitis Monthly;2024-06-10

2. Safety and Efficacy of LSG Versus LRYGB on Patients with Obesity: a Systematic Review and Meta-analysis from RCTs;Obesity Surgery;2024-02-14

3. Randomized controlled trials comparing gastric bypass, gastric band, and sleeve gastrectomy: A systematic review examining validity and applicability to wider clinical practice;Obesity Reviews;2024-02-12

4. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes;Diabetology & Metabolic Syndrome;2024-01-19

5. Digeda-4 decoction and its disassembled prescriptions improve dyslipidemia and apoptosis by regulating AMPK/SIRT1 pathway on tyloxapol-induced nonalcoholic fatty liver disease in mice;Journal of Ethnopharmacology;2023-12